Lifeloc Technologies, Inc.: Lifeloc Reports Second Quarter 2026 Results

Lifeloc Technologies (OTC:LCTC) reported Q2 2026 results for the quarter ended June 30. Net revenue rose to $2.445M from $2.219M in Q2 2025, while net loss narrowed to $134k ($0.05/share). Gross margin increased to 45%. The company also said it closed $500k financing at 10.5% interest and is targeting limited SpinDetect drug analyzer launch in Q1 2027.

Original reporting
Published Aug 13, 2026, 8:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 9:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$LCTC
Neutral
medium confidence
Mentioned
$LCTC
Relevance
6/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$LCTCNeutralLow
01

Why it matters

Traders may reprice the probability-weighted path to SpinDetect beta and limited commercial launch in Q1 2027, while also monitoring cash burn and the secured loan’s implications for balance-sheet risk.

02

Market read

The release provides fresh quarterly financial datapoints plus a concrete product development timeline (beta now, limited launch Q1 2027) and a secured financing update.

03

What to watch

The financing is secured by all assets at 10.5% with prime-rate adjustability, which can constrain flexibility if cash needs rise before the SpinDetect launch.

Relevance 6/10Novelty 6/10Timing: after-hours earnings release dated Aug 13, 2026

Background

Lifeloc is an OTC-listed developer/manufacturer of breath alcohol and drug testing devices, reporting Q2 2026 results and detailing progress on its SpinDetect oral-fluid analyzer.

Company-level read

Ticker impact

$LCTCNeutralMedium confidence
Context

Lifeloc reported Q2 2026 results, including $2.445M revenue, a $134K net loss, and a 10% YoY revenue increase.

Expected impact

Near-term trading likely hinges on whether investors focus on revenue growth and 45% gross margin versus continued net losses and financing terms.

Evidence & confidence

The article provides concrete quarterly revenue, net loss, and margin figures plus a financing update, but it does not include guidance or a clear catalyst beyond the planned SpinDetect beta and Q1 2027 launch.

Market effects

Breath alcohol and drug-testing device makers may see incremental sentiment from progress on an oral-fluid drug analyzer platform, but this is company-specific and not a sector-wide datapoint.

No clear regional macro linkage; operations and customers are described broadly across U.S. and international.

Limited global market relevance given OTC listing and company-specific product development timeline.

Counterpoint

Revenue growth and margin gains may be insufficient if continued R&D burn persists and the SpinDetect commercialization timeline slips beyond Q1 2027.

Key entities

  • Lifeloc Technologies, Inc.

    Subject of the earnings release, reporting Q2 2026 financials and SpinDetect development milestones.

  • SpinDetect Centrifugal Drug Analyzer

    Oral-fluid drug analyzer platform with disk-based chemistry; beta testing targeted and limited commercial launch planned for Q1 2027.

  • Chairman/CFO secured loan

    $500,000 loan closed during the quarter, secured by all assets, at 10.5% interest with prime-rate adjustability.

Related articles

$LCTCMed

Lifeloc Reports Third Quarter 2026 Results

Lifeloc Technologies, Inc (LCTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lifeloc Reports Third Quarter 2026 Results WHEAT RIDGE, Colo., November 16, 2026 -- Lifeloc Technologies, Inc. (OTCID: LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quar

$LCTCMed

Lifeloc Reports Second Quarter 2026 Results

Lifeloc Technologies, Inc (LCTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lifeloc Reports Second Quarter 2026 Results WHEAT RIDGE, Colo., August 13, 2026 -- Lifeloc Technologies, Inc. (OTCID: LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quart

$NVDAHighAI 9/10

What's Going On With Nvidia Stock Wednesday

Nvidia (NVDA) reported quarterly earnings of $2.68 per share on revenue of $115.84 billion, beating estimates. Data center sales reached $107.6 billion. The company raised its revenue forecast for the current quarter and long-term growth outlook, but expects no revenue from China. Nvidia also expanded its stock buyback program.

$DISMedAI 8/10

Disney’s Experiences Segment Hit Record Quarterly Revenue of $10.1 Billion as Cruise Days Surged. Can the Momentum Last?

Disney (DIS) reported Q4 2026 revenue of $25.95B, up 16% YoY, with its Experiences segment hitting a record $10.1B. All units grew, with Experiences leading in operating income at $2.25B. Adjusted net income rose 56% to $3.35B, beating estimates. The company plans to invest $60B in Experiences over a decade, focusing on parks and cruises.